TIDMAGL
RNS Number : 2654U
Angle PLC
23 October 2017
For immediate release 23 October 2017
ANGLE plc ("the Company")
RESEARCHERS DEVELOP PARSORTIX(TM) -BASED PROCESS TO EFFICIENTLY
HARVEST CANCER CELLS FROM BONE MARROW
Reactivation of such dormant cells has been implicated in
patients with cancer relapse
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that the Center for Women's Health
Tuebingen, Germany, has presented the first report on a successful
establishment of a protocol for detecting disseminated tumour cells
(DTCs) using cancer patient bone marrow with the Parsortix(TM)
system.
The reactivation of dormant DTCs and their release into the
bloodstream as circulating tumour cells (CTCs), is the process by
which a patient may, sometimes after many years of remission,
suffer a relapse through metastasis. There is intense interest in
the existence and status of such DTCs that are "hibernating" in the
bone marrow.
At present, the method of choice for detecting DTCs is a density
gradient centrifugation of the bone marrow to enrich for
mononuclear cells and then an antibody-based staining for various
cell markers. In experiments with spiked cancer cells this
procedure was shown to be accompanied by a tremendous reduction of
target cells with an average of up to 80% cell loss. This may well
be one reason why, in primary breast cancer, DTCs have been found
in the bone marrow of only 20-30% of patients.
The Tuebingen researchers have shown that their newly
established Parsortix(TM) based protocol allows a recovery of about
80% of input target cells. Furthermore, the Tuebingen team believe
that this easy to use method may well be applicable to other
(non-blood) body fluids for detection of tumor cells for liquid
biopsies.
The University Hospital Tuebingen research results were
presented in a poster at Europe's leading CTC conference, the Third
International Advances in Circulating Tumour Cells (ACTC)
Symposium. A copy of the poster is available at
https://angleplc.com/library/publications/.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The presence of disseminated tumour cells (DTCs) in bone marrow
has been shown in multiple studies to be predictive of clinical
relapse. The research from the Center for Women's Health in
Tuebingen demonstrates the utility of Parsortix(TM) in harvesting
disseminated cancer cells from bone marrow, extending the potential
applications of our liquid biopsy system significantly."
Dr. André Koch, Center for Women's Health, Tuebingen
commented:
"The Parsortix(TM) system shows huge promise in improving the
efficiency of isolating DTCs from bone marrow. At our Women's
Hospital, taking bone marrow is routine during surgery on breast
cancer patients, so improvements to processing and then analysis of
the bone marrow are particularly valuable. We are excited about the
opportunities this opens up."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes +44 (0) 203 705 9318
Nigel Birks +44 (0) 203 705 9316
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix(TM) system has a CE Mark
for Europe and FDA authorisation is in process for the United
States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESFMMZGNZNGNZM
(END) Dow Jones Newswires
October 23, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024